INVIVYD, INC. (IVVD) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$45.82M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$43.14M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$11.02M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$15.06M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$45.82M | (m) | (m) | (m) | $510.00K* | -$43.01M* | (m) | $29.37M | $29.46M | $0.00 |
| 2026-03-31 | Reported | (m) | -$43.14M | (m) | (m) | (m) | $726.00K | -$41.71M | (m) | $30.73M | $25.12M | $0.00 |
| 2025-09-30 | Reported | (m) | -$11.02M | (m) | (m) | (m) | $0.00* | -$8.25M* | (m) | $8.05M | $15.02M | $0.00 |
| 2025-06-30 | Reported | (m) | -$15.06M | (m) | (m) | (m) | $11.00K* | -$13.30M* | (m) | $9.57M | $16.59M | $0.00 |
| 2025-03-31 | Reported | (m) | -$16.92M | (m) | (m) | (m) | $144.00K | -$21.13M | (m) | $10.64M | $16.75M | $0.00 |
| 2024-09-30 | Reported | (m) | -$62.31M | (m) | (m) | (m) | $5.00K* | -$41.07M* | (m) | $57.85M | $12.96M | $0.00 |
| 2024-06-30 | Reported | (m) | -$49.25M | (m) | (m) | (m) | $0.00* | -$41.60M* | (m) | $30.33M | $21.09M | $0.00 |
| 2024-03-31 | Reported | (m) | -$46.09M | (m) | (m) | (m) | $140.00K | -$50.21M | (m) | $31.16M | $14.93M | $0.00 |
| 2023-09-30 | Reported | (m) | -$43.06M | (m) | (m) | (m) | $0.00* | -$35.35M* | (m) | $25.57M | $12.89M | $0.00 |
| 2023-06-30 | Reported | (m) | -$53.88M | (m) | (m) | (m) | -$9.00K* | -$37.39M* | (m) | $43.62M | $10.11M | $0.00 |
| 2023-03-31 | Reported | (m) | -$39.07M | (m) | (m) | (m) | $624.00K | -$41.18M | (m) | $27.20M | $11.04M | $0.00 |
| 2022-09-30 | Reported | (m) | -$47.33M | (m) | (m) | (m) | $477.00K* | -$56.14M* | (m) | $30.13M | $13.20M | $0.00 |
| 2022-06-30 | Reported | (m) | -$51.75M | (m) | (m) | (m) | $17.00K* | -$57.39M* | (m) | $37.13M | $14.62M | $0.00 |
| 2022-03-31 | Reported | (m) | -$100.74M | (m) | (m) | (m) | $0.00 | -$59.05M | (m) | $92.03M | $8.70M | $0.00 |
| 2021-09-30 | Reported | (m) | -$60.42M | (m) | (m) | (m) | $0.00* | -$54.21M* | (m) | $45.37M | $11.05M | $0.00 |
| 2021-06-30 | Reported | (m) | -$44.69M | (m) | (m) | (m) | (m) | -$33.57M* | (m) | $35.07M | $7.12M | $0.00 |
| 2021-03-31 | Reported | (m) | -$38.71M | (m) | (m) | (m) | (m) | -$23.74M | (m) | $34.03M | $3.68M | $0.00 |
| 2020-09-30 | Reported | (m) | -$48.01M | (m) | (m) | (m) | (m) | (m) | (m) | $7.25M | $842.00K | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$55.56M | (m) | (m) | (m) | $155.00K | -$58.13M | (m) | $38.31M | $66.93M | $0.00 |
| 2024-12-31 | Reported | (m) | -$176.88M | (m) | (m) | (m) | $140.00K | -$170.49M | (m) | $137.25M | $63.39M | $0.00 |
| 2023-12-31 | Reported | (m) | -$212.76M | (m) | (m) | (m) | $615.00K | -$173.16M | (m) | $158.66M | $49.13M | $0.00 |
| 2022-12-31 | Reported | (m) | -$248.03M | (m) | (m) | (m) | $1.71M | -$219.99M | (m) | $179.21M | $47.04M | $0.00 |
| 2021-12-31 | Reported | (m) | -$226.91M | (m) | (m) | (m) | $84.00K | -$184.74M | (m) | $182.89M | $36.52M | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |